314 related articles for article (PubMed ID: 8905746)
1. Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
Kyritsis AP; Yung WK; Jaeckle KA; Bruner J; Gleason MJ; Ictech SE; Flowers A; Levin VA
Neurosurgery; 1996 Nov; 39(5):921-6. PubMed ID: 8905746
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.
Levin VA; Lamborn K; Wara W; Davis R; Edwards M; Rabbitt J; Malec M; Prados MD
Neuro Oncol; 2000 Jan; 2(1):22-8. PubMed ID: 11302250
[TBL] [Abstract][Full Text] [Related]
3. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
4. Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance.
Levin VA; Prados MD
J Clin Oncol; 1992 May; 10(5):766-71. PubMed ID: 1314890
[TBL] [Abstract][Full Text] [Related]
5. Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas.
Levin VA; Wara WM; Davis RL; Vestnys P; Resser KJ; Yatsko K; Nutik S; Gutin PH; Wilson CB
J Neurosurg; 1985 Aug; 63(2):218-23. PubMed ID: 2991486
[TBL] [Abstract][Full Text] [Related]
6. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
Prados MD; Larson DA; Lamborn K; McDermott MW; Sneed PK; Wara WM; Chang SM; Mack EE; Krouwer HG; Chandler KL; Warnick RE; Davis RL; Rabbitt JE; Malec M; Levin VA; Gutin PH; Phillips TL; Wilson CB
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):57-63. PubMed ID: 9422558
[TBL] [Abstract][Full Text] [Related]
7. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
8. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR
Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
[TBL] [Abstract][Full Text] [Related]
9. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Walbert T; Gilbert MR; Groves MD; Puduvalli VK; Yung WK; Conrad CA; Bobustuc GC; Colman H; Hsu SH; Bekele BN; Qiao W; Levin VA
J Neurooncol; 2011 Apr; 102(2):273-80. PubMed ID: 20652724
[TBL] [Abstract][Full Text] [Related]
10. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors.
Levin VA; Edwards MS; Wright DC; Seager ML; Schimberg TP; Townsend JJ; Wilson CB
Cancer Treat Rep; 1980; 64(2-3):237-44. PubMed ID: 7407756
[TBL] [Abstract][Full Text] [Related]
11. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.
Levin VA; Silver P; Hannigan J; Wara WM; Gutin PH; Davis RL; Wilson CB
Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):321-4. PubMed ID: 2154418
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
Yang SH; Hong YK; Yoon SC; Kim BS; Lee YS; Lee TK; Lee KS; Jeun SS; Kim MC; Park CK
Oncol Rep; 2007 Jun; 17(6):1359-64. PubMed ID: 17487391
[TBL] [Abstract][Full Text] [Related]
13. Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas.
Jakacki RI; Jamison C; Mathews VP; Heilman DK; Dropcho E; Cornetta K; Macdonald DR; Williams DA
Med Pediatr Oncol; 1998 Dec; 31(6):483-90. PubMed ID: 9835900
[TBL] [Abstract][Full Text] [Related]
14. Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas.
Lancaster DL; Hoddes JA; Michalski A
J Neurooncol; 2003 Jul; 63(3):289-94. PubMed ID: 12892235
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for malignant gliomas.
Kyritsis AP
Oncology (Williston Park); 1993 Sep; 7(9):93-100; discussion 103, 106. PubMed ID: 8217533
[TBL] [Abstract][Full Text] [Related]
16. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery.
Rostomily RC; Spence AM; Duong D; McCormick K; Bland M; Berger MS
Neurosurgery; 1994 Sep; 35(3):378-88; discussion 388. PubMed ID: 7800129
[TBL] [Abstract][Full Text] [Related]
17. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas.
Levin VA; Prados MR; Wara WM; Davis RL; Gutin PH; Phillips TL; Lamborn K; Wilson CB
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):75-83. PubMed ID: 7721642
[TBL] [Abstract][Full Text] [Related]
18. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study.
Brandes AA; Ermani M; Turazzi S; Scelzi E; Berti F; Amistà P; Rotilio A; Licata C; Fiorentino MV
J Clin Oncol; 1999 Feb; 17(2):645-50. PubMed ID: 10080610
[TBL] [Abstract][Full Text] [Related]
19. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
Soffietti R; Nobile M; Rudà R; Borgognone M; Costanza A; Laguzzi E; Mutani R
Cancer; 2004 Feb; 100(4):807-13. PubMed ID: 14770438
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab is active as a single agent against recurrent malignant gliomas.
Agha CA; Ibrahim S; Hassan A; Elias DA; Fathallah-Shaykh HM
Anticancer Res; 2010 Feb; 30(2):609-11. PubMed ID: 20332478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
